Gastrointestinal STRING Test With Oral Immunotherapy

Not Recruiting

Trial ID: NCT04943744

Age - 5 Years-55 Years Gender - ALL Accepting Healthy Volunteers - No

Purpose

This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.

Official Title

Monitoring Gastrointestinal Responses In Food Oral Immunotherapy Using the Esophageal STRING Test

Stanford Investigator(s)

R. Sharon Chinthrajah
R. Sharon Chinthrajah

Associate Professor of Medicine (Sean Parker Center) and of Pediatrics (Allergy and Clinical Immunology)

Eligibility

Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial

* Able to swallow the EST.

Exclusion Criteria: • Allergy to, or inability to ingest, gelatin

-

View More
View Less

Intervention(s):

device: Entero-tracker

biological: omalizumab

biological: dupliumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2025 Stanford Medicine